The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of ...

PARIS, France I January 9, 2025 I Results from the investigational, randomized, open-label IRAKLIA phase 3 study demonstrated that Sarclisa administered at a ...

LONDON, UK & SAN FRANCISCO, CA, USA I January 09, 2025 I Verdiva Bio Limited (“Verdiva” or “the Company”) today announced its launch as a clinical-stage ...

CHICAGO, IL, USA I January 8, 2025 I Xentria, Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet medical ...

BEIJING, China I January 8, 2025 I In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide ...

Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily. SAN DIEGO, CA, USA I January 8, 2025 I Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), ...

PALO ALTO, CA and NEEDHAM, MA, USA and MELBOURNE, Australia I January 08, 2025 I Bitterroot Bio, a leader in developing innovative medicines in the field of ...

SEATTLE, WA, USA I January 7, 2025 I Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo ...

NEW YORK, NY, USA I January 07, 2025 I Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...

Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing and commercialization of potential best-in-class EGFR/HER3 ...

The Company has aligned on clinical plan based on a positive FDA meeting, leveraging clinical data from a first-in-human Phase 1 trial published today in ...

BEIJING, China & ALAMEDA, CA, China & TAIPEI, Taiwan I January 07, 2025 I Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a ...